Dr. Spring is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Boston, MA 02114- Is this information wrong?
Summary
- Dr. Laura Spring is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from University of Massachusetts Medical School. She specializes in breast cancer and is active in research.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2017- Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
University of Massachusetts Medical SchoolClass of 2011
Certifications & Licensure
ME State Medical License 2020 - 2026
MA State Medical License 2013 - 2026
FL State Medical License 2023 - 2025
NH State Medical License 2021 - 2025
RI State Medical License 2021 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Roles: Contact, Principal Investigator
- Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Start of enrollment: 2020 Dec 16
Roles: Principal Investigator, Contact, Sponsor-Investigator
- Sacituzumab Govitecan In TNBC Start of enrollment: 2020 Jul 14
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsAllosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier, Allison M Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom,...> ;Cancer Discovery. 2024 Feb 8
- HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell'Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A Yardley, Vandana Gupta Abramson, Carlos L Artea...> ;The Journal of Clinical Investigation. 2024 Feb 1
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.Emily J Gallagher, Heather Moore, Mario E Lacouture, Susan F Dent, Azeez Farooki, Marcus D Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura...> ;NPJ Breast Cancer. 2024 Jan 31
- Join now to see all
Journal Articles
- Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerSara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
- Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicLaura Spring, MD, The New England Journal of Medicine
- A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast CancerDavid T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research
Lectures
- Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.2019 ASCO Annual Meeting - 6/1/2019
- Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicJuly 2020
- Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicJuly 2020
- Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer During the Covid-19 PandemicJuly 2020
Press Mentions
Adjuvant Chemo Might Not Add Benefit in Breast Cancer Patients Who Have Excellent Response to Neoadjuvant ChemoDecember 5th, 2018
Breast Cancer Symptoms to Look Out ForDecember 7th, 2017- National Breast Cancer Awareness Month: Key Terms You Should KnowOctober 1st, 2017
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Newton-Wellesley HospitalNewton Lower Falls, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
